文献速递自身炎症与 IgG4 相关病

TURPAID队列的秋水仙碱抵抗预测标准不适用于JIR队列

Colchicine resistance prediction criteria from the TURPAID cohort do not apply to the JIR cohort: a multicentre descriptive analysis.
PubMed 文献 · RMD Open · 2026-02-18

该研究在236例经基因确诊并接受秋水仙碱治疗≥6个月的家族性地中海热(FMF)患者中,回顾性评估TURPAID评分对秋水仙碱抵抗的预测价值。结果显示,TURPAID评分≥2在89%的儿科和76%的成人秋水仙碱敏感患者中出现,ROC曲线下面积仅0.6。结论认为该评分在JIR队列中预测效果不佳,遗传权重过高导致过度分类。

要点

  • TURPAID评分在儿科和成人FMF中ROC曲线下面积均为0.6,区分度差。
  • 89%儿科和76%成人秋水仙碱敏感患者TURPAID评分≥2,过度分类明显。
  • MEFV外显子10突变计1.5分是降低预测准确性的主要因素。

核心结论

  • TURPAID评分在JIR队列中不能有效预测秋水仙碱抵抗。
  • 遗传结果应作为秋水仙碱抵抗预测评分的前提条件而非决定因素。

研究设计与样本

  • 回顾性分析236例经基因确诊并接受秋水仙碱治疗≥6个月的FMF患者。
  • 根据是否启动生物制剂治疗将患者分为秋水仙碱敏感组和抵抗组,并按年龄和性别匹配。
  • 回顾性应用TURPAID评分(范围0-4分,抵抗阈值≥2分),采用ROC曲线评估预测价值。

主要发现

  • TURPAID评分≥2在89%的儿科和76%的成人秋水仙碱敏感患者中观察到。
  • 儿科起病FMF患者的平均TURPAID评分显著更高。
  • ROC分析显示儿科和成人组的曲线下面积均为0.6。
  • 临床特征和发作模式随年龄而变化。
  • MEFV外显子10突变计1.5分导致过度分类,降低预测准确性。

关键数值与推荐

  • TURPAID评分范围0-4分,抵抗阈值≥2分。
  • 秋水仙碱抵抗操作定义为启动生物制剂治疗。

临床怎么用

  • 在更广泛人群中应用TURPAID评分预测秋水仙碱抵抗需谨慎。
  • 遗传结果应作为预测评分的前提而非决定因素。

局限性

  • 回顾性研究设计。
  • 可能存在回忆偏倚。
  • 年龄相关差异可能影响评分泛化性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease. Colchicine is the first-line treatment, yet 5-10% of patients are resistant, increasing the risk of complications like amyloidosis. In 2023, Batu et al proposed the Turkish Paediatric Autoinflammatory Diseases (TURPAID) score to predict colchicine resistance in paediatric FMF at diagnosis. Its utility in broader populations is unknown. We assessed its performance in paediatric and adult FMF patients from the international Juvenile Inflammatory Rheumatism (JIR) cohort. METHODS: We retrospectively analysed 236 genetically confirmed FMF patients treated with colchicine for ≥6 months. Patients were classified as colchicine-sensitive (CoS) or colchicine-resistant (CoR) based on the initiation of biologic therapy, which served as an operational definition of resistance, and matched for age and sex. The TURPAID score (range 0-4; resistance threshold ≥2) was retrospectively applied. Receiver operating characteristic (ROC) curves were used to assess predictive value. RESULTS: A TURPAID score ≥2 was observed in 89% of paediatric and 76% of adult CoS patients. Mean scores were significantly higher in paediatric-onset FMF. ROC analysis showed poor discrimination in both paediatric and adult groups (area under the curve=0.6). Clinical features and attack patterns varied by age. The genetic component (1.5 points for MEFV exon 10 mutations) contributed to overclassification, reducing predictive accuracy. CONCLUSION: The TURPAID score did not effectively predict colchicine resistance in the JIR cohort. Its limited generalisability may stem from age-related differences, recall bias and excessive genetic weighting. Genetic results should be a prerequisite and not a determinant of colchicine resistance prediction scores in FMF.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Mertz P, Elhani I, Koné-Paut I, et al. Colchicine resistance prediction criteria from the TURPAID cohort do not apply to the JIR cohort: a multicentre descriptive analysis. RMD Open. 2026. PMID: 41708156. doi:10.1136/rmdopen-2025-006409

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。